Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) Starts Presentation at 29th Annual Roth Conference
Peregrine Pharmaceuticals (NASDAQ: PPHM) is a biopharmaceutical company that researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. For more information, visit the company’s website at www.peregrineinc.com. About NetworkNewsWire NetworkNewsWire (NNW)…







